radiograph (P=0.031). These data suggest potentially consequential interruptions and delays in pulmonary TB diagnosis during the COVID-19 period.

Disclosures. Susan Butler-Wu, PhD, Cepheid (Consultant)

194. Progression of an Uncomplicated Urinary Tract Infection Among Female Patients with Susceptible and Non-Susceptible Urine Isolates: Findings from an Integrated Delivery Network
Jason Shafrin, PhD; Allen Marijam, MSc; Ashish V. Joshi, PhD; Fanny S. Mitran-Gold, MPH; Katie Eversen, MSc; Rifat Tuly, MPH; Peter Rosenquist, MSc; Michael Gillam, MD; Maria Elena Ruiz, MD; PRECISIONHealth, Los Angeles, CA; USA; GlaxoSmithKline plc, Collegeville, PA; GlaxoSmithKline plc, Collegeville, PA; PRECISIONHealth, Austin, TX; PRECISIONHealth, Washington, DC; MedStar Health, Washington, DC; MedStar Washington Hospital Center, Washington, DC
Session: O-39. UTIs

Background. Uncomplicated urinary tract infection (uUTI) is often treated empirically without antibiotic (AB) susceptibility testing; however, antimicrobial-resistant bacteria could lead to suboptimal treatment and progression to complicated UTI (cUTI). We examined the likelihood of uUTI progression to cUTI in patients with susceptible and non-susceptible uropathogens.

Methods. We performed a retrospective cohort study using data from a large Mid-Atlantic US integrated delivery network's electronic health records from July 1, 2016 to March 31, 2020. Patients included were female, aged ≥12 years with incident uUTI (diagnosis code or urine culture), and given an oral AB ≤5 days of diagnosis and ≥1 antibiotic susceptibility test. The primary outcome was progression to cUTI, defined as: new fever, nausea, or vomiting, in addition to uUTI symptoms; or receipt of intravenous antibiotic 3–28 days after index uUTI. Probability of progression to cUTI was assessed comparing patients with non-susceptible and susceptible isolates, with 1:1 propensity score matching. Patients retained for analysis had a nonzero predicted probability of being in the case and control group and were retained for analysis only if there were patients in the mirror group with similar propensity scores. Data were analyzed with logistic regression. Sensitivity analyses were performed to test the robustness of the primary analysis (Table).

Results. A total of 2565 patients were included: 1030 (40.2%) had non-susceptible isolates and 1535 (59.8%) had susceptible isolates. Mean age was 43.5 years and 59.9% of the cohort was White. After propensity score matching, patients with non-susceptible isolates were more than twice as likely to progress to cUTI versus patients with sensitive isolates (10.7% versus 4.9%; odds ratio, 2.35; p < 0.001; Figure). In sensitivity analyses, patients with non-susceptible isolates remained significantly more likely to progress to cUTI (p ≤ 0.009), excluding those receiving fluoroquinolones only (Table).

Conclusion. Patients with uUTI and AB-resistant isolates were significantly more likely to progress to cUTI than those with susceptible isolates. This finding highlights the need for greater understanding of antimicrobial resistance and has implications for the clinical management of uUTI.

Disclosures. Jason Shafrin, PhD, Precision Medicine Group (Employee, former employee of Precision Medicine Group, which received funding from GlaxoSmithKline plc to conduct this study) Alen Marijam, MSc, GlaxoSmithKline plc (Employee, shareholder) Ashish V. Joshi, PhD, GlaxoSmithKline plc (Employee, shareholder) Fanny S. Mitran-Gold, MPH, GlaxoSmithKline plc (Employee, shareholder) Katie Eversen, MSc, Precision Medicine Group (Employee, former employee of Precision Medicine Group, which received funding from GlaxoSmithKline plc to conduct this study) Rifat Tuly, MPH, Precision Medicine Group (Employee, former employee of Precision Medicine Group, which received funding from GlaxoSmithKline plc to conduct this study) Peter Rosenquist, MSc, Precision Medicine Group (Employee, former employee of Precision Medicine Group, which received funding from GlaxoSmithKline plc to conduct this study) Michael Gillam, MD, MedStar Health (Employee, employee of MedStar Health and received funding from GlaxoSmithKline plc through Precision Medicine Group to conduct this study) Maria Elena Ruiz, MD, Nothing to disclose.

195. Intraurethral to Oral Antibiotics Versus Intravaginal Antibiotics: A Step-Up or a Step-Down for Extended Spectrum Beta-Lactamase Producing Urinary Tract Infections?
Kelly C. Gamble, PharmD; Dustin T. Rose, PharmD, BCIDP, BCPS (AQ-ID), AAHIVP; Julia Sapozhnikov, PharmD, BCIDP; Ascension Seton, Austin, TX; Seton Healthcare Family, Austin, TX; Ascension Texas- Dell Children’s Medical Center of Central Texas, Austin, Texas
Session: O-39. UTIs

Background. The treatment of extended-spectrum beta-lactamase (ESBL)-producing urinary tract infections (UTI) may include either intravenous (IV) or oral (PO) antibiotics, according to the Infectious Diseases Society of America guidelines for resistant gram-negative organisms. The purpose of this study is to evaluate if PO step-down antibiotics, the switch group, compared to continued IV therapy in these UTIs affects clinical outcomes.

Methods. This multicenter retrospective cohort study was conducted in hospitalized patients with an ESBL-producing UTI between July 2016 and March 2020. The control group received a complete antibiotic course with a carbapenem; the switch group was transitioned to an oral agent within five days from initiation of a carbapenem. The primary endpoint was a composite all-cause clinical failure, which was defined as readmission or hospital mortality within 30 days of hospital discharge or a change in antibiotic during hospital admission. The secondary end points included individual components of the primary outcome, readmission indication, inpatient length of stay, direct antibiotic costs, and adverse events.

Results. The study included 153 patients: 95 and 58 patients in the control and switch groups, respectively. Demographics between the two groups were similar (Table 1). The mean ± SD duration of therapy was 11.7 ± 3.1 and 7.1 ± 3.3 days, respectively. Four oral agents were used for step-down therapy (Figure 1). The primary outcome occurred in 28% in both groups (27 vs 16 patients, p=0.91). The individual components of the primary outcome and readmission indication were also similar: readmission (93% vs 94%, p=0.95), readmission due to a recurrent UTI (33% vs 25%, p=0.73), hospital mortality (7% vs 6%, p=1.0), and change in antibiotic (0% vs 2%, p=0.38). The median (IQR) length of stay and direct antibiotic cost in the control and switch groups were 8 (5) vs 5 (2) days (p=0.01) and $278 ($244) vs $180 ($104) (p=0.01), respectively. Adverse events were similar in both groups except for diarrhea (15% vs 2%, p=0.01).

Table 1. Baseline Demographics. SD: standard deviation, ICU: intensive care unit, qSOFA: quick Sequential Organ Failure Assessment, ESBL: extended spectrum beta-lactamase, UTI: urinary tract infection

| Demographic | Control (n=95) | Switch (n=58) |
|-------------|--------------|--------------|
| Age, years (mean ± SD) | 68 ± 17 | 68 ± 19 |
| Male, n (%) | 28 (29.5) | 20 (34.5) |
| Race, (%) | | |
| Caucasian | 52 (54.7) | 36 (62.1) |
| Hispanic/Latino | 24 (25.3) | 12 (20.7) |
| African American | 19 (15.8) | 6 (10.3) |
| Other | 4 (4.2) | 4 (6.9) |
| Past Medical History, n (%) | | |
| Diabetes | 44 (46.3) | 28 (48.3) |
| Chronic kidney disease | 44 (46.3) | 48 (83.8) |
| Cardiovascular | 70 (75.7) | 44 (75.0) |
| Pulmonary | 10 (12.8) | 6 (10.5) |
| Malignancy | 17 (19.7) | 6 (10.5) |
| Charlson Comorbidity Score (mean ± SD) | 4.8 ± 1.7 | 4.5 ± 1.7 |
| ICU admission, n (%) | 26 (27.4) | 5 (8.6) |
| qSOFA (mean ± SD) | 1.0 ± 0.9 | 0.6 ± 0.7 |
| History of ESBL-producing organism, n (%) | 19 (20.5) | 9 (15.5) |

Table 2. Sensitivity analyses of the probability of uUTI progressing to cUTI in patients with non-susceptible versus susceptible isolates (matched population)

| Sensitivity analysis | Probability of progressing to cUTI |
|---------------------|----------------------------------|
| Baseline (100%) | 0.060 | <0.001 |
| Strict exclusion (n=661) | 0.039 | 0.009 |
| Excluding other infection (n=905) | 0.058 | <0.001 |
| QF-only (n=169) | 0.036 | 0.387 |

*Population size after matching; including only patients with a documented uUTI diagnosis and positive urine culture; including only patients with no other acute-care-acute infections within 14 days of index uUTI; including only patients initiating therapy with PO AB; QF was singled out because of as of 12 May 2016 a black-box warning has been added to the label and outcomes with QF are therefore of interest. Bold p-values are statistically significant (p < 0.05).

QF, uncomplicated urinary tract infection; PO, predominant urinary tract infection.
Figure 1. Oral Antibiotics. QD: once daily, BID: every 2 days, Q3D: every 3 days, DS tab: double strength tablet

Conclusion. There was no difference in clinical failure, readmission rate, mortality rate, or change in antibiotic between the control and switch groups; however, the switch group was associated with reduced hospital length of stay and direct antibiotic cost.

Disclosures. All Authors: No reported disclosures

196. Activity Impairment and Health-Related Quality of Life Associated with an Uncomplicated Urinary Tract Infection Among US Females

Jeffrey Thompson, PhD;1 Alan Marjiam, MSc;2 Fanny S. Mitrani-Gold, MPH;1 Jonathon Wright, BSc;1 Ashish V. Joshi, PhD;2 Kantar Health, New York, New York, USA, New York, New York 2GlaxoSmithKline plc.; Collegeville, PA, USA, Collegeville, Pennsylvania;3 GlaxoSmithKline plc. Collegeville, PA, USA, Chicago, Illinois

Session: O-39. UTIs

Background. Uncomplicated urinary tract infections (uUTI) are among the most common infections in women; however, there are few data on the impact of uUTIs on daily activity and health-related quality of life (HRQoL).

Methods. This was a prospective, cross-sectional survey of US females aged ≥ 18 years with a self-reported uUTI in the 60 days prior to participation. Participants were included if they received oral antibiotic treatment and participated in surveys fielded by Dynata, Lucid/Federated, or Kantar Profiles. See Table 1 for inclusion/exclusion criteria. Study objectives were to describe activity impairment (using the Activity Impairment Assessment [AIA]) and HRQoL (assessed with Short Form 36 version 2, Physical Component Score [PCS], Mental Component Score [MCS], and health utility index [SF-6D]) associated with uUTI. After screening, participants completed an online questionnaire on their most recent uUTI. Outcomes were reported with descriptive statistics, chi-squared tests, and t-tests. Analysis of HRQoL used 1:1 propensity score matching to compare to a matched US population from the 2020 National Health and Wellness Survey.

Table 1. Inclusion and exclusion criteria

| Inclusion criteria | Exclusion criteria |
|--------------------|-------------------|
| Female             | • Self-reported diagnosis of any of the following conditions indicative of uUTI in the 6-month period before oral antibiotic treatment for UUTI: urological abnormalities, urogenital infections, pelvic pain, menstrual pain, vaginal infections, genitourinary infections, or other urological conditions. |
| Age 12 years or older | • Any UUTI identified in the previous 60 days as having occurred during an inpatient hospitalization or stay at a long-term care facility. |
| A resident of the United States | • Initial UUT-associating antibiotic treatment received during an inpatient hospitalization. |
| Self-reported uUTI in the previous 60 days | • Pregnancy at the time of receiving UUT-associating oral antibiotic treatment. |
| Treatment with an oral antibiotic for UUTI | • Asymptomatic when diagnosed with a UUTI (i.e., only diagnosed due to a positive urine culture with no other UUTI symptoms present). |
| Ability to read English | • Diagnosis of COVID-19 in the past 12 months. |
| Provision of informed consent for the study | • See Table 2. Overall mean AIA score was 11.1/20 (higher score = more impairment). Most participants (58.7%) had a PCS that was the same or better than the matched population, while for MCS, most participants (52.8%) had scores well below the matched population average. Overall PCS, MCS, and SF-6D composite scores were 46.5, 40.0, and 0.63, respectively. These outcomes were significantly worse compared to the matched population, most notably MCS (Table 3). Stratification by number of antibiotics used revealed statistically significant differences in the effect of uUTI on exercise, PCS, SF-6D (based on use of 1 or ≥ 3 therapies), and on sleep (based on use of 2 or ≥ 3 therapies; Table 4). |

Disclosures. Jeffrey Thompson, PhD, Kantar Health (Employee, Employee of Kantar Health, which received funding from GlaxoSmithKline plc. to conduct this study) Alen Marjiam, MSc; GlaxoSmithKline plc. (Employee, Shareholder) Fanny S. Mitrani-Gold, MPH; GlaxoSmithKline plc. (Employee, Shareholder) Jonathon Wright, BSc; Kantar Health (Employee, Employee of Kantar Health, which received funding from GlaxoSmithKline plc. to conduct this study) Ashish V. Joshi, PhD, GlaxoSmithKline plc. (Employee, Shareholder)

Table 2. Activities impacted by uUTI

| Activities impacted by uUTI (N=375) | n (%) |
|------------------------------------|-------|
| Sexual intercourse                 | 251 (66.9) |
| Sleeping                           | 228 (60.8) |
| Exercise                           | 196 (52.3) |
| Housework/chores                   | 193 (51.5) |
| Social activities                   | 176 (46.9) |
| Shopping/running errands           | 145 (38.7) |
| Work outside the home              | 89 (23.7) |
| Studying                           | 29 (7.7) |
| Childcare                          | 24 (6.4) |
| Other                              | 21 (5.6) |

uUTI, uncomplicated urinary tract infection.

Table 3. Matched analysis of SF-36v2-measured HRQoL outcomes

| SF-6D outcomes | uUTI cohort N=375 | Matched US population* N=375 | Incremental burden of uUTI |
|----------------|-------------------|-------------------------------|---------------------------|
| Sexual intercourse | 11.2 (0.5) | 10.9 (0.5) | 0.3 (0.05) |
| Sleeping         | 15.2 (0.5) | 15.1 (0.5) | 0.1 (0.05) |
| Exercise         | 25.2 (0.5) | 25.1 (0.5) | 0.1 (0.05) |
| Housework/chores | 35.2 (0.5) | 35.1 (0.5) | 0.1 (0.05) |
| Social activities | 36.2 (0.5) | 36.1 (0.5) | 0.1 (0.05) |
| Physical Component Score (PCS) | 46.5 (0.5) | 46.3 (0.5) | 0.2 (0.05) |
| Mental Component Score (MCS) | 41.5 (0.5) | 41.4 (0.5) | 0.1 (0.05) |
| SF-6D Health Utility Index (SF-6D) | 0.65 (0.01) | 0.65 (0.01) | 0.0 (0.005) |

*Derived from the NHWS 2020; **Statistically significant difference (p < 0.0001); **PCS score displayed worse functioning compared to other acute infections (e.g., acute nosophymatitis [PC=46.0] and acute chelatide [PC=45.0]). SF-6D score at less than the same impact of both acute and chronic (e.g., acute nosophymatitis [MCS=41.6], acute chelatide [MCS=41.0] and osteoarthritis [MCS=41.7]). % score reduction of 0.37 is above the MCID threshold for SF-6D (mean 0.045)

HRQoL, health-related quality of life; MCID, minimal clinically important difference; MCS, mental component score; NHWS, National Health and Wellness Survey; PCS, physical component score; SD, standard deviation; SF-6D, health utility index; SF-36v2, short form version 2; uUTI, uncomplicated urinary tract infection.

Table 4. Outcomes stratified by number of oral antibiotics used to treat last UUTI

| Antibiotics used to treat last uUTI | Activities impacted by uUTI, n (%)
|------------------------------------|-------------------------------|
| 1 AB (n=235) | 2 AB (n=80) | ≥ 3 AB (n=60) |
| v1 vs v2 (p-value) | v1 vs v3 (p-value) | v2 vs v3 (p-value) |
| Sexual intercourse | 0.053 | 0.439 | 0.102 | 0.548 | 0.035 | 0.035 |
| Sex                    | 0.089 | 0.017 | 0.043 | 0.051 | 0.024 | 0.005 |
| Exercise               | 0.089 | 0.017 | 0.043 | 0.051 | 0.024 | 0.005 |
| Housework/chores       | 0.089 | 0.017 | 0.043 | 0.051 | 0.024 | 0.005 |
| Social activities       | 0.089 | 0.017 | 0.043 | 0.051 | 0.024 | 0.005 |
| Physical Component Score (PCS) | 0.089 | 0.017 | 0.043 | 0.051 | 0.024 | 0.005 |
| Health Utility Index (SF-6D) | 0.089 | 0.017 | 0.043 | 0.051 | 0.024 | 0.005 |
| SF-6D (SF-36v2) | 0.089 | 0.017 | 0.043 | 0.051 | 0.024 | 0.005 |

**Statistically significant difference (p < 0.05).**

*AB: antibiotic; AIA: activity impairment assessment; HRQoL; health-related quality of life; MCS: mental component score; PCS: physical component score; SD: standard deviation; SF-6D: short form version 2; UUTI, uncomplicated urinary tract infection.

Conclusion. uUTIs are significantly associated with adverse patient outcomes for daily activities and HRQoL, compounded by suboptimal treatment evident by the use of multiple antibiotics. MCS was notably affected, which is important as this is not often studied in uUTI.

Disclosures. Jeffrey Thompson, PhD, Kantar Health (Employee, Employee of Kantar Health, which received funding from GlaxoSmithKline plc. to conduct this study) Alen Marjiam, MSc; GlaxoSmithKline plc. (Employee, Shareholder) Fanny S. Mitrani-Gold, MPH; GlaxoSmithKline plc. (Employee, Shareholder) Jonathon Wright, BSc; Kantar Health (Employee, Employee of Kantar Health, which received funding from GlaxoSmithKline plc. to conduct this study) Ashish V. Joshi, PhD, GlaxoSmithKline plc. (Employee, Shareholder)